Open Orphan: Sustaining commercial traction
Open Orphan PLC, a specialist pharmaceutical services company, and the world leader in the testing of vaccines and antivirals using human challenge studies, continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities. The investment case centres on continuing to leverage its differentiated portfolio of assets and services, including converting a sales pipeline of non-COVID-19 related services worth over £110mln. A recently signed UK government contract valued up to £40mln is a game-changing opportunity to develop a funded COVID-19 challenge study. If this is successful, there are three government-sponsored vaccine development programmes lining up. The ongoing utility of the model is supported by the likely demand for multiple COVID-19 vaccines and antiviral treatments to meet global requirements.
Quick facts: Open Orphan PLC
Price: 28.5 GBX
Market Cap: £190.78 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE